Family of boy who died from brain-eating amoeba speaks out: 'Unimaginable'
Jaysen Carr died on July 18 after developing an infection from the brain-eating amoeba Naegleria fowleri, the statement shared by Bailey Law Firm said.
The South Carolina Department of Public Health confirmed in a statement to USA TODAY on July 23 that a person died after being exposed to the amoeba earlier in July.
Prisma Health Children's Hospital Midlands confirmed on July 22 that the person was treated at the facility but did not publicly identify the person.
"The Carr family is incredibly grateful for the outpouring of love from the community and for the dedicated care provided by the doctors and nurses at Prisma Health Children's Hospital in the Midlands," the statement said.
Brain-eating amoeba victim was 'bright and beloved' middle schooler
The statement from the Carr family's lawyer said Jaysen was a "bright and beloved" middle school student.
"His loss is unimaginable, and our hearts are with his family as they grieve their son and search for answers," the statement said.
The legal team said it will "stand beside this family not only to seek the truth, but to help ensure no other family endures a loss like this."
"We ask that you keep the Carrs in your thoughts and prayers and respect their privacy as they prepare to lay Jaysen to rest," Bailey Law Firm's statement said.
Brain-eating amoeba: Person dies from Naegleria fowleri in South Carolina, officials say
Family says boy was infected with brain-eating amoeba at SC lake
The family's statement also said Jaysen Carr developed the infection after swimming at Lake Murray outside Columbia.
The SCDPH said it also believed the exposure occurred at the lake.
"We cannot be completely certain as this organism occurs naturally and is present in many warm water lakes, rivers and streams," the agency said.
What is Naegleria fowleri? Why is it known as a brain-eating amoeba?
Naegleria fowleri is a type of amoeba that can cause a rare but nearly always fatal brain infection. It thrives in warm freshwater lakes, rivers and hot springs, according to the Centers for Disease Control and Prevention.
The amoeba is often referred to as brain-eating because it can cause an infection called primary amebic meningoencephalitis (PAM) that destroys brain tissue.
Most people who have been in bodies of waters have been exposed to the amoeba, but contact alone is not harmful, Dr. Anna Kathryn Burch, a pediatric infectious disease specialist at Prisma Health Children's Hospital Midlands, said during a news conference on July 22.
"Where it can cause an issue is if forceful water gets up the nose and is able to cross from the nose into the brain," Burch said, adding that a PAM infection causes the brain to swell.
To protect against a possible infection, the CDC recommends holding or wearing a nose clip when jumping into fresh water, keeping the head above water in hot springs and using distilled or boiled tap water when rinsing sinuses.
Melina Khan is a national trending reporter for USA TODAY. She can be reached at melina.khan@usatoday.com.
This article originally appeared on USA TODAY: 12-year-old dies from brain-eating amoeba after swimming in lake
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
SIGA to Host Business Update Call on August 5, 2025 Following Release of Second-Quarter 2025 Results
NEW YORK, July 29, 2025 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (Nasdaq: SIGA), a commercial-stage pharmaceutical company, today announced that management will host a webcast and conference call to provide a business update at 4:30 P.M. ET on Tuesday, August 5, 2025. Participating in the call will be Diem Nguyen, Chief Executive Officer, and Daniel Luckshire, Chief Financial Officer. A live webcast of the call will also be available on the Company's website at in the Investor Relations section of the site, or by clicking here. Please log in approximately 5-10 minutes prior to the scheduled start time. Participants may access the call by dialing 1-800-717-1738 for domestic callers or 1-646-307-1865 for international callers. A replay of the call will be available for two weeks by dialing 1-844-512-2921 for domestic callers or 1-412-317-6671 for international callers and using Conference ID: 1130215. The archived webcast will be available in the Investor Relations section of the Company's website. About SIGA SIGA is a commercial-stage pharmaceutical company and leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases. With a primary focus on orthopoxviruses, we are dedicated to protecting humanity against the world's most severe infectious diseases, including those that occur naturally, accidentally, or intentionally. Through partnerships with governments and public health agencies, we work to build a healthier and safer world by providing essential countermeasures against these global health threats. Our flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox (monkeypox), cowpox, and vaccinia complications. For more information about SIGA, visit Contacts:Suzanne Harnettsharnett@ and Investors Media Jennifer Drew-Bear, Edison GroupJdrew-bear@ Holly Stevens, CG Lifehstevens@
Yahoo
3 hours ago
- Yahoo
Sarepta shares rebound after shipments of gene therapy Elevidys resume in US
(Reuters) -Sarepta Therapeutics shares surged more than 30% before the bell on Tuesday, as analysts said the resumption of U.S. shipments for its muscular gene therapy partially removes financial headwinds and decreases the risk of market withdrawal. The company said on Monday it would resume shipments of Elevidys — approved in the U.S. to treat a rare condition called Duchenne muscular dystrophy — to patients who can walk. U.S. shipments to patients who cannot walk independently are still halted, following the death of two teenage boys earlier this year. These incidents brought heightened regulatory scrutiny to Sarepta in recent weeks, while the pause of shipments raised concerns about the future of Elevidys — the company's largest revenue generator. Sarepta's announcement followed the U.S. Food and Drug Administration's recommendation that the voluntary hold on shipments be removed after a probe showed the death of an 8-year-old boy in Brazil was not related to Elevidys. Wall Street analysts said the resumption of shipments would allow Sarepta to fulfill its near-term payments to partner Arrowhead and maintain access to its debt facilities. "The FDA's recommendation and the resumption of commercial treatment in the U.S. virtually eliminate the risk of Elevidys being formally withdrawn from the market," said William Blair analyst Sami Corwin. While the decision allows some patients to regain access to the treatment, analysts warned that patients and doctors could show hesitancy in light of the recent hit to reputation. "It remains to be seen how the news headlines regarding the patient deaths will affect commercial interest in the near term," Corwin said. Sarepta's partner Roche had also stopped Elevidys shipments in certain countries outside the U.S. Shares of Sarepta surged 36% to $18.85 in premarket trading. They have fallen more than 80% since the first Elevidys-related death was reported in March. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Forbes
3 hours ago
- Forbes
Sweeping Problems Under The Rug By The Feds Doesn't Make Them Go Away
A man walks his dog past a homeless man sleeping under a message painted on a boarded up shop in San ... More Francisco, California on April, 1, 2020, during the novel coronavirus outbreak. - The US death toll from the coronavirus pandemic topped 5,000 late on April 1, according to a running tally from Johns Hopkins University. (Photo by Josh Edelson / AFP) (Photo by JOSH EDELSON/AFP via Getty Images) For decades, every administration, every Congress, put many things off for someone else to deal with. No one can get everything done all the time, that's understandable. But many current economic and social programs aren't a result of juggling what might be possible. Instead, they have become the ultimate attempt to kick every can down the road. That doesn't solve problems. It only hides them and allows them to grow and fester. One of the current examples is homelessness. Here is a statement out of the presidential executive order, Ending Crime And Disorder On America's Streets: 'The overwhelming majority of these individuals are addicted to drugs, have a mental health condition, or both. Nearly two-thirds of homeless individuals report having regularly used hard drugs like methamphetamines, cocaine, or opioids in their lifetimes. An equally large share of homeless individuals reported suffering from mental health conditions.' Homelessness is a problem in many parts of the country. And, yes, people on the streets are often troubled in one way or another. However, the entire executive order is a rhetorical setup, claiming that 'nearly two-thirds' of the individuals reporting having used 'hard drugs like methamphetamines, cocaine, or opioids in their lifetimes.' No source for the statistic that is then delivered to deemphasize that any such use might have been long before. And then a statement that an 'equally large share of homeless individuals reported suffering from mental health conditions.' No source, again, and no explanation of what mental health conditions mean. Broadly defined enough, like any amount of depression, anxiety, discomfort, and so on, it could include everyone in the country. Next, a combination of claiming that spending by the federal government and states has run tens of billions on failed programs 'that address homelessness but not its root causes.' After claiming that homeless people leave 'other citizens vulnerable to public safety threats' comes the statement, 'Shifting homeless individuals into long-term institutional settings for humane treatment through the appropriate use of civil commitment will restore public order.' After stating that previous spending never looked at root causes, presuming that the administration knows the root causes, the proffered solution is to lock people away. The message is to ignore the problem and put it out of sight. The point isn't really for safety, because most dangerous behavior in the country doesn't come from homeless people. It's for comfort and to pretend everything is fine. This has economic and social implications. Institutionalize where? Privately owned prisons where someone makes a lot of money from incarcerations? Hospitals that have been financially struggling but will even more now that Medicaid has been so thoroughly cut? Similar issues come in arguments over diversity, equity, and inclusion, or DEI. The administration wants it purged not only from websites and government discussions, but from corporations, universities, and anywhere else the term might appear. Again, the communication expressed by action is to strike any mention of the topic anywhere, to bury it from consciousness as though that makes issues go away. It never does. Other parts of life are no different. Corporations want to promote the use of the most recent forms of artificial intelligence. Traditionally, the argument executives would use is not that technology was about enabling job cuts, but to free people up to do more useful and interesting work. That mask has finally begun to slip as CEOs and their corporations boast of shrinking their workforces. Ultimately, this will lead to fewer people being employed, greater degrees of consumer financial struggle, and economic weakness. But, again, that all gets brushed under the carpet. No society can long stand with such undermining. So long as problems are ignored, they likely grow worse until there comes a point that they demand more resources than are available.
